AbbVie said it will buy cancer biotech Pharmacyclics in a $21 billion deal that returns the Chicago drug company to deal-making after backing away from a big tax-lowering takeover last year.
via WSJ.com: US Business http://ift.tt/1NiJHag
via WSJ.com: US Business http://ift.tt/1NiJHag
Nessun commento:
Posta un commento